Correction

Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial Infarction

N Engl J Med 1995; 333:267July 27, 1995

Article

Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial Infarction (Special Article, N Engl J Med 1995:332;1418 - 1424) . On page 1423, the sentence that begins in line 9 of the right-hand column should have read, “It would cost the nation approximately $500 million each year but would also provide 38,500 additional years of life for patients after myocardial infarction,” not 3.5 million, as printed.

Citing Articles (1)

Citing Articles

1. 1

   Barry F Uretsky, Richard G Sheahan. (1997) Primary Prevention of Sudden Cardiac Death in Heart Failure: Will the Solution Be Shocking?. Journal of the American College of Cardiology 30:7, 1589-1597
   CrossRef